ADL negatives are a dubious disease in the field of blood tumors, with complex clinical outcomes and often involving multi-system fatigue. Early identification and standardized diagnosis are essential for improving prognosis. The diagnosis of the disease requires a combination of clinical outcomes, imaging inspections, laboratory tests and pathological activation.
The platform can assist in matching a team of authoritative experts at home and abroad to provide accurate diagnosis and treatment programs. In recent years, with the development of treatment-oriented, immune-regulatory therapy and precision medicine, many previously difficult to treat blood tumour diseases have been significantly improved. Treatment requires close monitoring of efficacy and adverse reactions, adapted to timely regimens according to changes in the disease.
Multidisciplinary collaboration (MDT) is particularly important for the integrated management of ALK negatives for interstitial large cell lymphoma. 2. Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment programs; 3.
Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.